OpGen Announces 2016 Fourth Quarter and Year End Financial Results
“In 2016 our investments in genomics and informatics for infectious disease management issues caused by multi-drug resistant organisms began to pay off. We successfully moved our Acuitas Rapid Test for drug resistant genes and pathogens and our
2016 Year End and Fourth Quarter Financial Results
- Revenue: Total revenue for the full year ended December 31, 2016 was
$4.0 million, a 27% increase from the $3.2 million in 2015. Total revenue for the fourth quarter of 2016 was $1.0 million, a decrease of 24% from $1.3 million in the fourth quarter of 2015 and an increase of 32% from the $0.8 million in the third quarter of 2016.
- Operating Expenses: Operating expenses for the full year ended December 31, 2016 were
$23.0 millioncompared with $18.2 millionin 2015. Operating expenses for the fourth quarter of 2016 were $5.7 millioncompared with $6.2 millionin the fourth quarter of 2015.
- Net Loss: Net loss for the full year ended December 31, 2016 was
$19.2 millioncompared with $17.4 millionin 2015. Net loss for the fourth quarter of 2016 was $4.8 millioncompared to $4.7 millionin the fourth quarter of 2015.
- Cash Position: Cash and cash equivalents were $4.1 million as of December 31, 2016 compared with $4.3 million as of September 30, 2016.
2016 Enterprise Highlights and Recent Developments:
- Announced collaboration with Merck to develop novel rapid diagnostics and informatics tools to combat antibiotic resistance. The companies will collaborate to support OpGen’s development of rapid DNA tests and a genomic knowledgebase of antibiotic-resistant pathogens for predicting antibiotic susceptibility based on test results. Under the terms of the agreement, Merck will provide access to its archive of over 200,000 bacterial pathogens gathered over the last 15 years through the Study for Monitoring Antimicrobial Resistance Trends (SMART), one of the world’s largest surveillance studies of antimicrobial resistance.
- Successfully moved the Acuitas Rapid Test and genome-based antibiotic resistance analysis technology from research into development phase, including transitioning our informatics infrastructure and genomic development engine into production and initial performance verification of top pathogens.
- Participated with the District of Columbia Hospital Association as key technology provider to complete the first citywide quantification of multidrug-resistant organism (MDRO) prevalence in Washington, D.C. healthcare facilities. The results revealed the prevalence of carbapenem-resistant enterobacteriaceae (CRE) and other carbapenem-resistant organisms (CRO) was 5.1% and 6.4%, respectively.
- Announced completion of the Intermountain Healthcare retrospective MDRO health outcomes study. The study is the largest of its kind conducted in an integrated health system and is anticipated to provide significant insights into how healthcare systems can reduce infections and improve health outcomes.
- Completed a
$10.4million Private Placement in the second quarter and raised $4.7 million during the fourth quarter of 2016 under a previously announced “at the market” (ATM) offering.
- Participated in nine posters and oral presentations at major medical meetings and published analytical validation results for the Acuitas MDRO Gene Test.
“During 2017 we are focused on advancing the development of the Acuitas brand of rapid diagnostic products alongside the Acuitas Lighthouse Knowledgebase with a goal of implementing the technology for external research use in the second half of the year,” continued Mr. Jones. “We are also working to further accelerate the growth of our business in
In the fight to help address the global antibiotic resistance crisis, OpGen expects to advance the following business objectives in 2017:
- Genomic and antibiotic resistance testing of 10,000 multidrug resistant organisms to support initial development of the first Acuitas Rapid Test kits and deployment of the Acuitas Lighthouse Knowledgebase.
- Completion of initial Acuitas Rapid Test development and
Acuitas Lighthousegenotype/phenotype predictive algorithms and clinical performance verification.
- Presentation of Acuitas Rapid Test and performance data at medical meetings and in peer reviewed journals.
- Announcement of in vitro diagnostic instrument supply and cooperation agreement to support global commercialization of the Acuitas Rapid Test.
- Establishment of distribution and partner relationships to support commercialization of the Acuitas Rapid Test and the Acuitas Lighthouse Knowledgebase in international markets.
- Establishment of Acuitas Rapid Test early access and performance verification programs to support regulatory approval clinical trials and publications.
- Continued efforts to obtain third party development funding for Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase development and deployment.
Conference Call Information
OpGen management will hold a conference call today beginning at 4:30 p.m. (EDT) to discuss fourth quarter and year end financial results and other business activities. The call can be accessed by dialing 844-420-8185 (domestic) or 216-562-0481 (international) and providing passcode 87850606. A live webcast of the conference call can be accessed by visiting the Investor Relations section of the company’s website at http://ir.opgen.com. A replay of the webcast will be available shortly after the conclusion of the call on the company’s website for 90 days.
A telephone replay also will be available at
This press release includes statements relating to the company's products and services, its commercialization plans for these products and services, and its product and services development efforts. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory approval for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission (
|Consolidated Statements of Operations and Comprehensive Loss|
|Three Months Ended December 31,||Twelve Months Ended December 31,|
|Cost of products sold||388,581||391,515||1,658,571||1,179,771|
|Cost of services||102,600||169,111||631,333||367,802|
|Research and development||2,334,407||2,105,892||8,613,236||6,002,941|
|General and administrative||1,647,512||2,140,499||6,602,608||5,834,642|
|Sales and marketing||1,246,646||1,342,889||5,529,274||4,305,444|
|Total operating expenses||5,719,746||6,150,593||23,035,022||18,216,883|
|Interest and other (expense)/income||(2,889)||1,411||(5,967)||26,657|
|Foreign currency transaction losses||(10,395)||—||(8,102)||—|
|Change in fair value of derivative financial instruments||—||—||—||(647,342)|
|Total other expense||(46,825)||(37,485)||(157,416)||(2,422,005)|
|Loss before income taxes||(4,760,008)||(4,858,491)||(19,166,753)||(17,481,168)|
|Provision for income taxes||—||(130,757)||—||(129,095)|
|Preferred stock dividends and beneficial conversion||—||—||(332,550)||(243,762)|
|Net loss available to common stockholders||$(4,760,008)||$(4,727,734)||$(19,499,303)||$(17,595,835)|
|Net loss per common share - basic and diluted||$(0.21)||$(0.38)||$(1.10)||$(2.20)|
|Weighted average shares outstanding - basic and diluted||22,549,773||12,540,755||17,667,557||7,980,995|
|Other comprehensive income/(loss) - foreign currency translation||6,176||(1,010)||7,235||(1,059)|
|Consolidated Balance Sheets|
|December 31, 2016||December 31, 2015|
|Cash and cash equivalents||$||4,117,324||$||7,814,220|
|Accounts receivable, net||542,420||678,646|
|Prepaid expenses and other current assets||329,646||566,239|
|Total current assets||5,681,758||9,885,117|
|Property and equipment, net||800,723||1,074,710|
|Intangible assets, net||1,620,998||1,888,814|
|Other noncurrent assets||279,752||270,327|
|Liabilities and Stockholders’ Equity|
|Accrued compensation and benefits||578,480||1,081,270|
|Short-term notes payable||1,023,815||—|
|Current maturities of long-term capital lease obligation||184,399||251,800|
|Total current liabilities||5,271,937||4,590,073|
|Long-term capital lease obligation and other noncurrent liabilities||146,543||328,642|
|Common stock, $0.01 par value; 200,000,000 shares authorized; 25,304,270 and 12,547,684 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively||253,042||125,477|
|Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and
outstanding at December 31, 2016 and December 31, 2015, respectively
|Additional paid-in capital||136,199,382||121,490,994|
|Accumulated other comprehensive income/(loss)||6,176||(1,059||)|
|Total stockholders’ equity||3,167,481||7,491,046|
|Total liabilities and stockholders’ equity||$||8,984,045||$||13,756,496|
Michael FarmerDirector, Marketing 240-813-1284 email@example.com InvestorRelations@opgen.com OpGen Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong781-591-3443 firstname.lastname@example.org